皇冠体育注册平台www.hg108.vip)是一个开放皇冠体育即时比分、皇冠体育官网注册的平台。皇冠体育注册平台(www.hg108.vip)专业解决皇冠体育会员怎么申请开户、怎么申请皇冠体育信用盘代理、皇冠体育公司的代理怎么拿的问题。

KUALA LUMPUR: Duopharma Biotech Bhd and the government have executed the agreement to procure insulin medicines via direct negotiation for RM375.17 million, a Bursa Malaysia filing said.

The company said wholly-owned subsidiary Duopharma Marketing Sdn Bhd (DMktg) will supply and deliver the products to the Health Ministry while Biocon Sdn Bhd, the manufacturer, will pack and label the products under the agreement.

Biocon's human insulin formulation will be supplied to all MoH hospitals, district health offices and health clinics.

,

soi cầu xsmb ngày hôm nay(www.84vng.com):soi cầu xsmb ngày hôm nay(www.84vng.com) cổng Chơi tài xỉu uy tín nhất việt nam。soi cầu xsmb ngày hôm nay(www.84vng.com)game tài Xỉu soi cầu xsmb ngày hôm nay online công bằng nhất,soi cầu xsmb ngày hôm nay(www.84vng.com)cổng game không thể dự đoán can thiệp,mở thưởng bằng blockchain ,đảm bảo kết quả công bằng.

,

The three-year agreement is from Apr 29, 2022 to Apr 28, 2025. It may be extended based on terms and conditions to be agreed on by the parties.

Malaysia has an estimated 3.9 million diabetics, with 420,000 using human insulin in the government hospitals and clinics.

DMktg and Biocon hope to improve diabetes management in the country by providing high quality and cost-effective biosimilar insulins. - Bernama


转载说明:本文转载自Sunbet。,

足球投注appwww.hg108.vip)是皇冠体育官网线上直营平台。足球投注app面向亚太地区招募代理,开放皇冠信用网代理申请、皇冠现金网代理会员开户等业务。足球投注app可下载皇冠官方APP,皇冠APP包括皇冠体育最新代理登录线路、皇冠体育最新会员登录线路。

ag区块链百家乐声明:该文看法仅代表作者自己,与阳光在线无关。转载请注明:皇冠体育注册平台(www.hg108.vip):Duopharma, govt execute agreement for insulin worth RM375.17mil via direct negotiation
发布评论

分享到:

www.a55555.net彩票网:PETRONAS, DNV sign MoU for carbon capture utilisation and storage
1 条回复
  1. usdt官方交易平台(www.usdt8.vip)
    usdt官方交易平台(www.usdt8.vip)
    (2022-11-27 00:07:53) 1#

    新2手机网址www.hg108.vip)实时更新发布最新最快的新2手机网址、新2手机网址线路、新2手机网址登录网址、新2手机网址管理端、新2手机网址手机版登录网址、新2手机皇冠登录网址。
    情节超合理

发表评论

◎欢迎参与讨论,请在这里发表您的看法、交流您的观点。